Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924533 | 0.93 | L3MBTL1 (0.44) | PTGDR2ALDH1A1KDM4ECNR1USP2 | |
| SCHEMBL4140420 | 0.89 | KMT2A (0.44) | PTGDR2ALDH1A1LMNAHSD17B10CNR1 | |
| SCHEMBL4151537 | 0.88 | KDM4E (0.47) | PTGDR2ALDH1A1LMNAHSD17B10KDM4E | |
| SCHEMBL3917987 | 0.88 | GAA (0.44) | ALDH1A1LMNAHSD17B10CNR1USP2 | |
| SCHEMBL3597643 | 0.87 | CNR1 (0.39) | PTGDR2ALDH1A1LMNACNR1CYP1A2 | |
| SCHEMBL3596115 | 0.87 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10CNR1TSHR | |
| SCHEMBL3590430 | 0.86 | CNR1 (0.41) | PTGDR2ALDH1A1LMNACNR1TSHR | |
| SCHEMBL3605409 | 0.85 | EPHX2 (0.40) | ALDH1A1LMNACNR1GAA | |
| SCHEMBL3914118 | 0.84 | LMNA (0.45) | ALDH1A1LMNAHSD17B10KDM4EUSP2 | |
| SCHEMBL3912621 | 0.83 | L3MBTL1 (0.46) | KDM4ECNR1TSHRCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209552-A1 | Organic Compounds | NOVARTIS AG | 2009-08-20 | — | — | US | claimed |
| US-20090209552-A1 | Organic Compounds | NOVARTIS AG | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209552-A1 | Organic Compounds | SLCO1B3, SLCO1B1, SLC10A6 | PTGDR2 1741/4885ALDH1A1 439/4885LMNA 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.